Cerus RedeS Phase 3 Trial Meets Primary Endpoint for INTERCEPT Red Blood Cells
What the Cerus RedeS result means for blood safety technology: a Phase 3 win on haemoglobin, an investigational US status and open commercial questions.
Tag: INTERCEPT Blood System
Read More